Outcome Prediction in Pediatric Fever in Neutropenia: Development of Clinical Decision Rules and External Validation of Published Rules Based on Data from the Prospective Multicenter SPOG 2015 FN Definition Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Aug 2

PMID 37531403

Authors

Marina Santschi

Roland A Ammann

Philipp K A Agyeman

Marc Ansari

Nicole Bodmer

Eva Brack

Christa Koenig

Affiliations

Soon will be listed here.

Abstract

Background: Fever in neutropenia (FN) remains a serious complication of childhood cancer therapy. Clinical decision rules (CDRs) are recommended to help distinguish between children at high and low risk of severe infection. The aim of this analysis was to develop new CDRs for three different outcomes and to externally validate published CDRs.

Procedure: Children undergoing chemotherapy for cancer were observed in a prospective multicenter study. CDRs predicting low from high risk infection regarding three outcomes (bacteremia, serious medical complications (SMC), safety relevant events (SRE)) were developed from multivariable regression models. Their predictive performance was assessed by internal cross-validation. Published CDRs suitable for validation were identified by literature search. Parameters of predictive performance were compared to assess reproducibility.

Results: In 158 patients recruited between April 2016 and August 2018, 360 FN episodes were recorded, including 56 (16%) with bacteremia, 30 (8%) with SMC and 72 (20%) with SRE. The CDRs for bacteremia and SRE used four characteristics (type of malignancy, severely reduced general condition, leucocyte count <0.3 G/L, bone marrow involvement), the CDR for SMC two characteristics (severely reduced general condition and platelet count <50 G/L). Eleven published CDRs were analyzed. Six CDRs showed reproducibility, but only one in both sensitivity and specificity.

Conclusions: This analysis developed CDRs predicting bacteremia, SMC or SRE at presentation with FN. In addition, it identified six published CDRs that show some reproducibility. Validation of CDRs is fundamental to find the best balance between sensitivity and specificity, and will help to further improve management of FN.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Koenig C, Bodmer N, Agyeman P, Niggli F, Adam C, Ansari M . 39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health. 2020; 4(7):495-502. DOI: 10.1016/S2352-4642(20)30092-4. View

Srinivasan A, Kumar N, Scott J . Evaluation of serum procalcitonin, serum interleukin-6, and interleukin-8 as predictors of serious infection in children with febrile neutropenia and cancer. Indian J Cancer. 2021; 58(2):185-189. DOI: 10.4103/ijc.IJC_808_18. View

Phillips R, Lehrnbecher T, Alexander S, Sung L . Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One. 2012; 7(5):e38300. PMC: 3365042. DOI: 10.1371/journal.pone.0038300. View

Santolaya M, Alvarez A, Becker A, Cofre J, Enriquez N, ORyan M . Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001; 19(14):3415-21. DOI: 10.1200/JCO.2001.19.14.3415. View

Hemming V, Jakes A, Shenton G, Phillips B . Prospective cohort study of procalcitonin levels in children with cancer presenting with febrile neutropenia. BMC Pediatr. 2017; 17(1):2. PMC: 5217195. DOI: 10.1186/s12887-016-0766-8. View

Klaassen R, Goodman T, Pham B, Doyle J . "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000; 18(5):1012-9. DOI: 10.1200/JCO.2000.18.5.1012. View

Haeusler G, Phillips R, Slavin M, Babl F, De Abreu Lourenco R, Mechinaud F . Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. EClinicalMedicine. 2020; 23:100394. PMC: 7329706. DOI: 10.1016/j.eclinm.2020.100394. View

Baorto E, Aquino V, Mullen C, Buchanan G, DeBaun M . Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer. 2001; 92(4):909-13. DOI: 10.1002/1097-0142(20010815)92:4<909::aid-cncr1400>3.0.co;2-h. View

10.

Haeusler G, Thursky K, Slavin M, Babl F, De Abreu Lourenco R, Allaway Z . Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine. 2020; 18:100220. PMC: 6978200. DOI: 10.1016/j.eclinm.2019.11.013. View

11.

Rondinelli P, Ribeiro K, de Camargo B . A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006; 28(10):665-70. DOI: 10.1097/01.mph.0000212996.94929.0b. View

12.

Kesik V, Atas E, Kurt Y, Aydin F, Babacan O, Gulgun M . Adrenomedullin predicts high risk and culture positivity in children with solid tumors suffering from neutropenic fever. J Infect Chemother. 2016; 22(9):617-21. DOI: 10.1016/j.jiac.2016.06.007. View

13.

Segulja S, Ruzic A, Dujmic D, Bazdaric K, Roganovic J . Simple predictors of the re- occurrence of severe febrile neutropenia episode: a single-center retrospective cohort study in pediatric patients with malignant diseases. Croat Med J. 2019; 60(1):20-25. PMC: 6406065. View

14.

Morgan J, Cleminson J, Atkin K, Stewart L, Phillips R . Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer. 2016; 24(6):2651-60. DOI: 10.1007/s00520-016-3074-9. View

15.

van der Galien H, Loeffen E, Miedema K, Tissing W . Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Support Care Cancer. 2018; 26(11):3819-3826. PMC: 6182367. DOI: 10.1007/s00520-018-4249-3. View

16.

Haeusler G, Thursky K, Mechinaud F, Babl F, De Abreu Lourenco R, Slavin M . Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study. Br J Cancer. 2017; 117(2):171-178. PMC: 5520507. DOI: 10.1038/bjc.2017.154. View

17.

De Pietri S, Frandsen T, Christensen M, Grell K, Rathe M, Muller K . Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2020; 68(1):e28793. DOI: 10.1002/pbc.28793. View

18.

Oberoi S, Das A, Trehan A, Ray P, Bansal D . Can complications in febrile neutropenia be predicted? Report from a developing country. Support Care Cancer. 2017; 25(11):3523-3528. DOI: 10.1007/s00520-017-3776-7. View

19.

Suttitossatam I, Satayasai W, Sinlapamongkolkul P, Pusongchai T, Sritipsukho P, Surapolchai P . Predictors of severe adverse outcomes in febrile neutropenia of pediatric oncology patients at a single institute in Thailand. Pediatr Hematol Oncol. 2020; 37(7):561-572. DOI: 10.1080/08880018.2020.1767243. View

20.

Hakim H, Flynn P, Srivastava D, Knapp K, Li C, Okuma J . Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2009; 29(1):53-9. DOI: 10.1097/INF.0b013e3181c3f6f0. View